# A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence

> **NCT03945799** · PHASE1,PHASE2 · TERMINATED · sponsor: **Zhejiang University** · enrollment: 28 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Anlotinib Hydrochloride

## Key facts

- **NCT ID:** NCT03945799
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-22
- **Primary completion:** 2022-06-25
- **Final completion:** 2022-06-25
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** The study has gotten preliminary results and stopped advanced.
- **Last updated:** 2022-08-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03945799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03945799, "A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT03945799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*